Troglitazone decreases serum uric acid concentrations in type II diabetic patients and non-diabetics.
Iwatani
M
M
Wasada
T
T
Katsumori
K
K
Watanabe-Takahashi
C
C
Kamatani
N
N
Iwamoto
Y
Y
D001786:Blood Glucose / Q000378:metabolism; D002839:Chromans / Q000494:pharmacology* / Q000627:therapeutic use*; D003404:Creatinine / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000188:drug therapy; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D007328:Insulin / Q000097:blood; D008875:Middle Aged; D012016:Reference Values; D013844:Thiazoles / Q000494:pharmacology* / Q000627:therapeutic use*; D045162:Thiazolidinediones; D000077288:Troglitazone; D014527:Uric Acid / Q000097:blood*
D001786:Blood Glucose; D002839:Chromans; D003404:Creatinine; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin; D013844:Thiazoles; D045162:Thiazolidinediones; D000077288:Troglitazone; D014527:Uric Acid